REG - GlaxoSmithKline PLC - Board and Committee Changes

GSKAnnouncement

06/05/2021 17:55

RNS Number : 8440X
  
GlaxoSmithKline PLC
  
06 May 2021
  
 

 
GlaxoSmithKline plc
 
GSK announces changes to its Board and Committees
 
GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021.
 
As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee. 
 
In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee.  
 
Note
 



1.


From 6 May 2021 the Board of GSK comprises 
 








Sir Jonathan Symonds  
Emma Walmsley                       
Iain Mackay                               
Dr Hal Barron                
Vindi Banga                  
Charles Bancroft 
Dr Anne Beal
Dr Vivienne Cox                        
Lynn Elsenhans             
Dr Jesse Goodman                   
Dr Laurie Glimcher                     
Urs Rohner                                


Non-Executive Chairman
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer and President, R&D
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
 



 
V A Whyte
Company Secretary
 
6 May 2021
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOABLGDUCSGDGBL